October 16, 2025Open Access

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: A study protocol for open-label, randomized phase III trial (OptiRiMoxTB)

View Full Paper

Ask AI

Bookmark

The trial aims to determine if a four-month treatment with optimized rifampicin improves patient outcomes compared to the standard six-month regimen.
Participants will be administered either rifampicin alone or in combination with moxifloxacin, with a focus on TB-free survival and safety measures.
Conducted in four African countries, this randomized phase III trial will include 414 newly diagnosed adults following strict protocols for treatment assignment.
Results may inform future treatment protocols for managing drug-susceptible tuberculosis, emphasizing shorter treatment durations.

Discussion

No takes yet. Share an insight, caveat, or question.

This open-label trial tests a four-month regimen of rifampicin with or without moxifloxacin for efficacy and safety in drug-susceptible tuberculosis.

Mlyuka et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This open-label trial tests a four-month regimen of rifampicin with or without moxifloxacin for efficacy and safety in drug-susceptible tuberculosis.